by Erik Valent | Aug 26, 2020 | Uncategorized
The European Commission has validated the amendment request of the MMpredict consortium to extend the project duration with 6 month to 31th of October 2020. Due to the COVID-19 outbreak the finalization of the project was hampered since all planned interactions and...
by Erik Valent | Aug 26, 2020 | Uncategorized
Watch the interesting webinar on personalized medicine organized by Myeloma Patients Europe (MPE). In this webinar, Dr. Francesca Bonello from the Università degli Studi di Torino, Turin, Italy – provided examples of the individualized therapy options including future...
by Erik Valent | Jan 2, 2020 | Uncategorized
Validation of SKY92 high and low risk prognostication in a retrospective, multinational cohort of 155 non-trial multiple myeloma patients Yan-Ting Chen1, Erik T. Valent1, Erik H. van Beers1, Rowan Kuiper1, Stefania Oliva2, Torsten Haferlach3, Wee-Joo Chng4, Martin H....
by Erik Valent | Jul 31, 2019 | Uncategorized
In two video interviews – recorded by the Myeloma Patients Europe – Dr. Annemieke Van Dongen-Leunis from the Erasmus School of Health Policy and Management, Erasmus University Rotterdam, explains the results of the research conducted within the MMpredict...
by Erik Valent | Jul 31, 2019 | Uncategorized
Watch the interesting webinar on personalised medicine organized by Myeloma Patients Europe (MPE). In this webinar, Dr Annemiek Broijl from the Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands – provided examples of the...
